FDA Drug recall D-0322-2024
Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister car…
- FDA Drug
- Class III
- ongoing
- Published 2024-02-21
On 2024-02-21 the FDA classified a Class III recall of Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister car… by Teva Pharmaceuticals Usa, citing discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0322-2024 |
| Classification | Class III |
| Status | ongoing |
| Initiated | 2024-01-25 |
| Published | 2024-02-21 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Teva Pharmaceuticals Usa |
| Distribution | US |
Product
Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58
Reason
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
Identifiers
| ndc | 0555-9012-79 |
|---|---|
| ndc | 0555-9012-58 |
| code_info | Lot #: 100040731, Exp 7/31/2024 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0322-2024%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.